KIF5B and neoplasm: Although the highest dosage of selpercatinib and pralsetinib (30 mg per kg BID) showed moderate anti-tumor effect against Ba/F3 KIF5B–RETG810R allograft tumors (Fig. 7d), there was not a commensurate decrease in phosphorylation of the RETG810R mutant (Fig. 7e), suggesting that these effects may be due to off-target effects.